Resurgent Financial Advisors LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

Resurgent Financial Advisors LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 12.1% during the first quarter, HoldingsChannel reports. The institutional investor owned 28,170 shares of the biopharmaceutical company’s stock after acquiring an additional 3,031 shares during the quarter. Resurgent Financial Advisors LLC’s holdings in Pfizer were worth $714,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Clarity Asset Management Inc. bought a new stake in Pfizer during the 4th quarter valued at approximately $27,000. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares during the period. North Capital Inc. purchased a new stake in Pfizer in the 1st quarter worth $28,000. Bernard Wealth Management Corp. purchased a new stake in Pfizer in the 4th quarter worth $30,000. Finally, Horizon Financial Services LLC purchased a new stake in Pfizer in the 1st quarter worth $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $24.46 on Friday. The company’s 50-day moving average is $24.07 and its two-hundred day moving average is $24.74. The firm has a market capitalization of $139.06 billion, a price-to-earnings ratio of 17.72, a PEG ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.82 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.03%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio is presently 124.64%.

Analysts Set New Price Targets

Several analysts have recently issued reports on PFE shares. Bank of America upped their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Morgan Stanley raised their target price on shares of Pfizer from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 30th. Citigroup raised their target price on shares of Pfizer from $23.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Finally, TD Cowen dropped their price objective on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.